Academic Frontline｜New Study on Nature Medicine (IF 82.9) Titled TORCHLIGHT Illuminates the Road of Survival for Patients with Triple-negative Breast Cancer, Participated by Prof. Zhou Xin of Prof. Zeng Xiaohua's Team

On January 8, 2024, a research report on an innovative breast cancer study led by Prof. Jiang Zefei from the Fifth Medical Center of the Chinese People's Liberation Army General Hospital, in which Prof. Zhou Xin from the team of Prof. Zeng Xiaohua from the Breast Cancer Center of Chongqing University Cancer Hospital participated, was published online in the international top medical journal Nature Medicine (IF: 82.9) with the title "TORCHLIGHT".

It is reported that this study, as a combination of "Chinese scholars + local new medicine", is the first randomized controlled study on the efficacy and safety of first-line treatment of advanced triple-negative breast cancer with albumin-bound nab-paclitaxel ± toripalimab. The four-year study has pooled the wisdom and efforts of more than 50 research centers nationwide, including the Breast Cancer Center of Chongqing University Cancer Hospital. The Breast Cancer Center of Chongqing University Cancer Hospital is the only participating research center in the Chongqing region, and its enrollment number and quality are among the top in the study.

The interim analysis of the study initially showed that for first-line treatment of patients with advanced triple-negative breast cancer, albumin-bound nab-paclitaxel ± toripalimab significantly improved survival compared to the control group, and the safety was acceptable, providing patients with a promising new treatment strategy. "TORCHLIGHT" lights up the survival path for patients with triple-negative breast cancer!

Source: Jiang, Z., Ouyang, Q., Sun, T. et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med 30, 249–256 (2024). https://doi.org/10.1038/s41591-023-02677-x